Starling Oncology, Inc. (STLN)
Snapshot
- 1 week
- -0.6%+1.1% vs SPY
- 1 month
- -1.6%+0.7% vs SPY
- Market cap
- $624.9M
- P/E
- negindustry 37.9
- P/B
- -25.8
- EV/EBITDA
- -31.5
- FCF yield
- -0.5%
- Short % float
- 7.5%
- Days to cover
- 5.6
- Short change
- -3.8%
- Consensus
- Buy3 buy · 0 hold · 0 sell
- Price target
- $9.00+44.0% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Starling Oncology, Inc. (STLN). Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
- Daniel Virnich FACHECEO & Executive DirectorUSD 700K
- Yale D. PodnosChief Medical OfficerUSD 597K
- Robert CarterChief Financial OfficerUSD 509K
- Austin LeeVP of Accounting & Controller
- Jordan McInerneyChief Development Officer
- Mark HueppelsheuserGeneral Counsel
Snapshot
Price & returns1 month -1.6%
- 1 week
- -0.6%+1.1% vs SPY
- 1 month
- -1.6%+0.7% vs SPY
ValuationP/E neg vs industry 37.9 · market cap $624.9M
- Market cap
- $624.9M
- P/E
- negindustry 37.9
- P/B
- -25.8
- EV/EBITDA
- -31.5
- FCF yield
- -0.5%
Short interest & optionsshort 7.5% of float
- Short % float
- 7.5%
- Days to cover
- 5.6
- Short change
- -3.8%
Street & earningsTarget $9.00 (+44.0% upside)3 buy · 0 hold · 0 sell
- Consensus
- Buy3 buy · 0 hold · 0 sell
- Price target
- $9.00+44.0% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Starling Oncology, Inc. (STLN). Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
- Daniel Virnich FACHECEO & Executive DirectorUSD 700K
- Yale D. PodnosChief Medical OfficerUSD 597K
- Robert CarterChief Financial OfficerUSD 509K
- Austin LeeVP of Accounting & Controller
